New antibody aims to keep myeloma at bay after transplant

NCT ID NCT07409454

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This phase 2 trial tests a bispecific antibody called CM336 as maintenance therapy after stem cell transplant in 20 adults with newly diagnosed multiple myeloma who still have minimal residual disease. The goal is to see if it can clear remaining cancer cells and delay relapse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BCMA/CD3 bispecific antibody (CM336)
What this could lead to: If successful, this could offer a new maintenance option to keep multiple myeloma in check after stem cell transplant, potentially delaying relapse.
What could go wrong: This is a small, early-phase trial with only 20 participants and no comparison group. The treatment may cause side effects and may not improve long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
RECRUITING

Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.